



## APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

January 7, 2021 1:00 PM EST

Apollomics-Am-Ch\_logo-medium

GlycoMimetics\_logo

**Foster City, CA, Hangzhou, China, Gaithersburg, MD, January 7, 2021** — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).

"This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "AML is an aggressive disease and relapsed/refractory patients have an extremely poor prognosis. We look forward to initiating our Phase 3 bridging study this year and working with the CDE on a potentially accelerated clinical development program to address this important patient need."

In September 2020, the NMPA CDE granted Investigational New Drug (IND) approval for APL-106 enabling the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML.

The BTD is part of the revised Drug Registration Regulation that became effective in July 2020 in China. The BTD is designed to expedite the development and review of therapies that are being developed for treatment of serious diseases for which there is no existing treatment or where preliminary evidence indicates significant advantages of the therapy over available treatment options.<sup>1</sup>

### About Uproleselan (APL-106)

Discovered and developed by GlycoMimetics, uproleselan (APL-106) is a late clinical-stage, potentially first-in-class, targeted inhibitor of E-selectin. Uproleselan (yoo' pro le' sel an) is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In 2017, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for treatment of adults with relapsed or refractory AML. Apollomics licensed APL-106 from GlycoMimetics in January 2020 to develop and commercialize APL-106 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

### About Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow. It is an aggressive disease that causes the bone marrow to produce immature cells that are unable to carry out their normal function and develop into leukemic white blood cells called myeloblasts. In the U.S., there are approximately 20,000 new cases of AML each year and a 5-year survival rate of 28.7%.<sup>2</sup> The annual incidence of new cases of AML in China is 21,600, and relapsed/refractory AML has an extremely poor prognosis.<sup>3</sup>

### About Apollomics, Inc.

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit [www.apollomicsinc.com](http://www.apollomicsinc.com).

### About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with two late-stage clinical development programs and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

### Forward-Looking Statements

This press release contains forward-looking statements, including those relating to the planned or potential clinical development of uproleselan and engagement with regulatory authorities, as well as the potential benefits and impact of the product candidate. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements as they relate to GlycoMimetics, as well as other risks facing GlycoMimetics, please see the risk factors described in the GlycoMimetics annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2020, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

<sup>1</sup>China Drug Registration Regulation: [http://www.gov.cn/gongbao/content/2020/content\\_5512563.htm](http://www.gov.cn/gongbao/content/2020/content_5512563.htm)

<sup>2</sup>National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program

<sup>3</sup>Yang Xiaofeng, Zhang Sufen, Zhang Qingyuan. *Practical Therapeutics of Hematological Diseases[M]*. Military Medical Science Press, 2008.

### Apollomics Contact Information:

#### Investor Contact:

Wilson W. Cheung  
Chief Financial Officer  
(650) 209-4436  
[wcheung@apollomicsinc.com](mailto:wcheung@apollomicsinc.com)

#### China Media Contact:

Porda Havas International Finance Communications Group

Kelly Fung

Phoenix Fung

General Manager  
(852) 3150 6763  
[kelly.fung@pordahavas.com](mailto:kelly.fung@pordahavas.com)

Assistant Vice President  
(852) 3150 6773  
[phoenix.fung@pordahavas.com](mailto:phoenix.fung@pordahavas.com)

**U.S. Media Contact:**

Remy Bernarda  
Corporate Communications  
(415) 203-6386

**GlycoMimetics Contacts**

Investor Contact:  
Shari Annes  
Phone: 650-888-0902  
Email: [sannes@annesassociates.com](mailto:sannes@annesassociates.com)

Media Contact:  
Jamie Lacey-Moreira  
Phone: 410-299-3310  
Email: [jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)